# Indigo Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indigo-biosystems

- Industry: Software
- Headquarters: Indianapolis, US
- Website: www.indigobio.com
- Total disclosed funding: $8.5M
- Latest round: Series B (Jun 12, 2014)
- Investors on record: 1

## About

Indigo Biosystems is a provider of laboratory automation and data analytics solutions, focusing on enhancing efficiency and compliance in scientific workflows across various sectors.Founded in 2006, Indigo Biosystems operates from Indianapolis, US, and specializes in laboratory automation technology. The company has not undergone any significant pivots or changes in its business strategy and does not have subsidiaries. The CEO and founder, Randall Julian, has a history in entrepreneurship. The company raised USD 8.5 mn in its Series B funding round on June 12, 2014, led by Bootstrap Venture Partners, marking a total fundraising of USD 8.5 mn across five deals.Indigo BioAutomation specializes in advanced laboratory automation and data analytics solutions, primarily through its flagship products, ASCENT and ARQ. ASCENT is designed for chromatography and mass spectrometry, enhancing workflow efficiency and data insights while ensuring compliance with Quality practices and standard operating procedures (SOPs). ARQ caters to PCR workflows, facilitating streamlined performance and simplifying complex data analysis. The solutions are tailored for clinical and life science laboratories, addressing the challenges of managing vast amounts of data and complex instrumentation. The company serves a diverse client base, including leading laboratories and test manufacturers across North America, Europe, and Asia, all of which benefit from the seamless integration and operational transformation enabled by Indigo's offerings.Indigo BioAutomation generates revenue through a Software as a Service (SaaS) model, where clients subscribe to access its advanced software solutions, including ASCENT and ARQ. This subscription-based structure allows laboratories to leverage the full capabilities of Indigo's products from anywhere, enhancing operational efficiency. Clients typically engage in annual contracts, facilitating ongoing access to updates and support. Revenue is derived primarily from B2B transactions with laboratories, clinical facilities, and research institutions that require high-throughput data analysis and automation solutions. The pricing structure reflects the sophisticated nature of the software and its integration into laboratory workflows, ensuring that users can achieve enhanced performance and compliance.Indigo Biosystems is focusing on developing new products to support laboratory workflows and enhance data analytics capabilities; however, specific product launch dates have not been disclosed. The company is also considering geographic expansion into new markets, targeting regions in Europe and Asia by the end of 2025. The recent funding of USD 8.5 mn raised in June 2014 will be utilized to support these initiatives, including investing in product development and market entry strategies.

## Funding rounds

- Series B, Jun 12, 2014, $8.5M — Bootstrap Venture Partners

## Investors

- Bootstrap Venture Partners (https://capitalatlas.ai/funds/bootstrap-venture-partners) — Series B